• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Clene Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket

    6/16/23 8:10:56 AM ET
    $AUVI
    $CELZ
    $CLNN
    $COHN
    Building Products
    Consumer Discretionary
    Finance: Consumer Services
    Finance
    Get the next $AUVI alert in real time by email

    Gainers

    • Evelo Biosciences, Inc. (NASDAQ:EVLO) shares gained 192.8% to $0.2427 in pre-market trading. Evelo Biosciences was granted U.S. patent #11672834 for "Prebiotic Compositions And Methods Of Use Thereof For Modulation Of The Microbiome."
    • Plutonian Acquisition Corp. (NASDAQ:PLTNR) shares surged 42.4% to $0.47 in pre-market trading after jumping 32% on Thursday.
    • Humanigen, Inc. (NASDAQ:HGEN) shares rose 39.2% to $0.2227 in pre-market trading. Humanigen recently presented promising new hematologic data from PREACH-M trial for chronic myelomonocytic leukemia treatment at the 2023 European Hematology Association Congress.
    • Virgin Galactic Holdings, Inc. (NYSE:SPCE) shares rose 38.7% to $5.63 in pre-market trading as the company announced the start of commercial spaceline operations. The company said its first commercial spaceflight, "Galactic 01," is set to fly between June 27 and June 30.
    • COMSovereign Holding Corp. (NASDAQ:COMS) gained 26.4% to $2.34 in pre-market trading.
    • Nikola Corporation (NASDAQ:NKLA) gained 24.3% to $1.74 in pre-market trading after gaining around 30% on Thursday. The EV maker also gained last week after shareholders reportedly rejected the company's proposal to issue more stock shares.
    • FingerMotion, Inc. (NASDAQ:FNGR) shares gained 23.2% to $2.50 in pre-market trading after climbing over 18% on Thursday.
    • Cohen & Company Inc. (NYSE:COHN) rose 20.8% to $5.45 in pre-market trading.
    • OpGen, Inc. (NASDAQ:OPGN) shares climbed 16.9% to $0.7133 in pre-market trading. OpGen, last month, posted a wider-than-expected quarterly loss.
    • Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) rose 9.2% to $0.1960 in pre-market trading. MEI Pharma and Infinity Pharmaceuticals, said that the companies will host a recorded joint video webcast that will be available at 8:00 am Eastern Time on June 19, 2023.

    Losers

    • Applied UV, Inc. (NASDAQ:AUVI) fell 33.2% to $1.27 in pre-market. Applied UV retained Quantiva to integrate AI and machine learning capabilities into its PURONetaAnd Airocide Systems.
    • Clene Inc. (NASDAQ:CLNN) fell 20.1% to $0.8399 in pre-market trading after the company reported the launch of proposed public offering. Clene’s CNM-Au8 treatment demonstrated a statistically significant reduction of plasma neurofilament light chain levels compared to placebo at 24 weeks.
    • Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) fell 15.3% to $4.80 in pre-market trading after jumping around 25% on Thursday. The company recently reported a $2 million buyback program.
    • SCWorx Corp. (NASDAQ:WORX) fell 14.3% to $0.3209 in pre-market trading after gaining over 70% on Thursday.
    • EdtechX Holdings Acquisition Corp. II (NASDAQ:EDTX) shares dropped 13.5% to $29.39 in pre-market trading after jumping 207% on Thursday. The company announced Wednesday an amendment to extend the date to consummate a business combination from June 15, 2023 to Dec. 15, 2023.
    • Leju Holdings Limited (NYSE:LEJU) shares dropped 11.5% to $3.39 in pre-market trading after gaining 31% on Thursday.
    • VIQ Solutions Inc. (NASDAQ:VQS) shares fell 10.5% to $0.3111 in pre-market trading. VIQ Solutions shares gained 32% on Thursday after the company partnered Justice AV Solutions to bring AI-generated draft transcripts of courtroom proceedings.
    • Tenon Medical, Inc. (NASDAQ:TNON) fell 10.5% to $0.3031 in pre-market trading after adding 16% on Thursday. Tenon Medical recently priced its public offering of $5.6M at $0.56 per unit.
    • Verastem, Inc. (NASDAQ:VSTM) fell 10.3% to $9.70 in pre-market trading after the company reported a proposed public offering of common stock and pre-funded warrants.
    • Planet Green Holdings Corp. (NYSE:PLAG) fell 10.1% to $0.8995 in pre-market trading after surging around 33% on Thursday.

     

    Now Read This: Investor Sentiment Improves Further After Dow Jumps Over 400 Points

    Get the next $AUVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AUVI
    $CELZ
    $CLNN
    $COHN

    CompanyDatePrice TargetRatingAnalyst
    Verastem Inc.
    $VSTM
    2/4/2026$18.00Buy
    H.C. Wainwright
    Verastem Inc.
    $VSTM
    10/16/2025Overweight
    Cantor Fitzgerald
    Virgin Galactic Holdings Inc.
    $SPCE
    6/30/2025$3.00Neutral
    Goldman
    Verastem Inc.
    $VSTM
    4/10/2025$15.00Buy
    Jefferies
    Verastem Inc.
    $VSTM
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    Verastem Inc.
    $VSTM
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    Nikola Corporation
    $NKLA
    11/7/2024Buy → Neutral
    Bryan Garnier
    Verastem Inc.
    $VSTM
    9/30/2024$13.00Buy
    Guggenheim
    More analyst ratings

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Verastem with a new price target

    H.C. Wainwright initiated coverage of Verastem with a rating of Buy and set a new price target of $18.00

    2/4/26 8:31:21 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Verastem

    Cantor Fitzgerald resumed coverage of Verastem with a rating of Overweight

    10/16/25 8:50:56 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman resumed coverage on Virgin Galactic with a new price target

    Goldman resumed coverage of Virgin Galactic with a rating of Neutral and set a new price target of $3.00

    6/30/25 8:07:24 AM ET
    $SPCE
    Transportation Services
    Consumer Discretionary

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Leong Yew Poh decreased direct ownership by 6% to 160,000 units (SEC Form 4)

    4 - FingerMotion, Inc. (0001602409) (Issuer)

    12/29/25 6:26:12 AM ET
    $FNGR
    Computer Software: Prepackaged Software
    Technology

    Director Leong Yew Poh decreased direct ownership by 6% to 170,000 units (SEC Form 4)

    4 - FingerMotion, Inc. (0001602409) (Issuer)

    12/8/25 7:08:12 AM ET
    $FNGR
    Computer Software: Prepackaged Software
    Technology

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by EVP, CFO and Treasurer Pooler Joseph W. Jr.

    4 - Cohen & Co Inc. (0001270436) (Issuer)

    3/6/26 4:06:25 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Chief Executive Officer Brafman Lester Raymond

    4 - Cohen & Co Inc. (0001270436) (Issuer)

    3/6/26 4:05:52 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 4 filed by Executive Chairman Cohen Daniel G

    4 - Cohen & Co Inc. (0001270436) (Issuer)

    3/6/26 4:05:18 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cohen & Company Reports Fourth Quarter & Full Year 2025 Financial Results

    Board Declares Quarterly Dividend of $0.25 per Share and Special Dividend of $0.70 per Share Revenue of $102.7 Million in Fourth Quarter 2025 and $275.6 Million in Full Year 2025 Net Income Attributable to Cohen & Company Inc. of $8.1 Million, or $1.48 per Diluted Share, in Fourth Quarter 2025 and $14.4 Million, or $4.35 per Diluted Share, in Full Year 2025 Adjusted Pre-Tax Income of $18.3 Million, or $2.97 per Diluted Share, in Fourth Quarter 2025 and $41.4 Million, or $6.92 per Diluted Share, in Full Year 2025 PHILADELPHIA and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Cohen & Company Inc. (NYSE:COHN) today reported financial results for its fourth quarter and full year ended Decem

    3/6/26 8:00:00 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Cohen & Company Sets Release Date for Fourth Quarter & Full Year 2025 Financial Results

    PHILADELPHIA and NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Cohen & Company Inc. (NYSE:COHN) will release its financial results for the fourth quarter and full year ended December 31, 2025 on Friday, March 6, 2026. The Company will host a conference call at 10:00 a.m. Eastern Time (ET) that day to discuss these results. The conference call will be available via webcast. Interested parties can access the webcast by clicking the webcast link on the Company's homepage at www.cohenandcompany.com. Those wishing to listen to the conference call with operator assistance can dial (877) 524-8416 (domestic) or +1 (412) 902-1028 (international). A replay of the call will be available for three day

    3/4/26 4:15:00 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates

    AVMAPKI™ FAKZYNJA™ CO-PACK net product revenues of $17.5 million for the fourth quarter of 2025 and $30.9 million for the full year 2025, following accelerated U.S. FDA approval in May 2025 Based on FDA guidance, Company to develop Phase 2 registration-directed protocols to evaluate VS-7375, a highly selective, oral KRAS G12D (ON/OFF) inhibitor with best-in-class potential, in 2L PDAC, 2L/3L NSCLC and 2L+ CRC in combination with cetuximab Cleared multiple dose levels of VS-7375 with no DLTs, continuing dose escalation to 1200 mg QD; cleared 600 mg QD dose level of VS-7375 in combination with cetuximab with no DLTs; continuing higher dose evaluations Company cash, cash equivalents, and

    3/4/26 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $CELZ
    $CLNN
    $COHN
    SEC Filings

    View All

    Cohen & Company Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Cohen & Co Inc. (0001270436) (Filer)

    3/6/26 4:05:49 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    SEC Form 10-K filed by Cohen & Company Inc.

    10-K - Cohen & Co Inc. (0001270436) (Filer)

    3/6/26 12:48:57 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Cohen & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cohen & Co Inc. (0001270436) (Filer)

    3/6/26 8:20:38 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Leadership Updates

    Live Leadership Updates

    View All

    Cohen & Company Announces Appointment of Pawel Skonieczka as Managing Director to Lead Coverage of Space Technology, Aerospace, & Communications Infrastructure in Capital Markets Segment

    NEW YORK, Feb. 26, 2026 /PRNewswire/ -- After nearly doubling deal flow and closing $43 billion in transactions in 2025, Cohen & Company Capital Markets ("CCM"), a division of Cohen & Company Securities, LLC, an indirect, controlled subsidiary of Cohen & Company Inc. (NYSE:COHN), announced the appointment of Pawel Skonieczka as a Managing Director to lead the expansion of the firm's advisory capabilities across Space Technology, Aerospace, and Communications Infrastructure. Mr. Skonieczka brings nearly two decades of experience advising public and private companies, financial sp

    2/26/26 10:43:00 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Cohen & Company Announces Appointment of Senior Leadership to Expand Energy and Energy Transition Capabilities

    Firm Launches Houston Office Strategic Hire Anchors Firm's Expansion Across Energy, Power, and Infrastructure PHILADELPHIA and NEW YORK, Jan. 12, 2026 /PRNewswire/ -- After nearly doubling deal flow and closing $44 billion in transactions in 2025, Cohen & Company Capital Markets, a division of Cohen & Company Securities, LLC, an indirect, controlled subsidiary of Cohen & Company Inc. (NYSE:COHN), today announced the appointment of senior leadership to its Energy and Energy Transition team, along with the opening of its Houston office to serve as the firm's hub for energy and energy transition advisory services.

    1/12/26 8:00:00 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth

    John Johnson, current board member, appointed to chairman of the board Michael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of development Commercial launch progresses as RAMP 301 Phase 3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027 Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced strategic leadership changes to accelerate its next phase of growth. Michael Kauffman, M.D., Ph.D., currently lead director of the Board, has been appointed as the president of development and will jo

    12/15/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Financials

    Live finance-specific insights

    View All

    Cohen & Company Reports Fourth Quarter & Full Year 2025 Financial Results

    Board Declares Quarterly Dividend of $0.25 per Share and Special Dividend of $0.70 per Share Revenue of $102.7 Million in Fourth Quarter 2025 and $275.6 Million in Full Year 2025 Net Income Attributable to Cohen & Company Inc. of $8.1 Million, or $1.48 per Diluted Share, in Fourth Quarter 2025 and $14.4 Million, or $4.35 per Diluted Share, in Full Year 2025 Adjusted Pre-Tax Income of $18.3 Million, or $2.97 per Diluted Share, in Fourth Quarter 2025 and $41.4 Million, or $6.92 per Diluted Share, in Full Year 2025 PHILADELPHIA and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Cohen & Company Inc. (NYSE:COHN) today reported financial results for its fourth quarter and full year ended Decem

    3/6/26 8:00:00 AM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Cohen & Company Sets Release Date for Fourth Quarter & Full Year 2025 Financial Results

    PHILADELPHIA and NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Cohen & Company Inc. (NYSE:COHN) will release its financial results for the fourth quarter and full year ended December 31, 2025 on Friday, March 6, 2026. The Company will host a conference call at 10:00 a.m. Eastern Time (ET) that day to discuss these results. The conference call will be available via webcast. Interested parties can access the webcast by clicking the webcast link on the Company's homepage at www.cohenandcompany.com. Those wishing to listen to the conference call with operator assistance can dial (877) 524-8416 (domestic) or +1 (412) 902-1028 (international). A replay of the call will be available for three day

    3/4/26 4:15:00 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results and business updates on Wednesday, March 4, 2026, at 4:30 pm ET. To access the conference call, please dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) and enter the passcode 7321921 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's websit

    2/18/26 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AUVI
    $CELZ
    $CLNN
    $COHN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Cohen & Company Inc.

    SC 13D/A - Cohen & Co Inc. (0001270436) (Subject)

    12/3/24 4:18:04 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance

    Amendment: SEC Form SC 13D/A filed by Cohen & Company Inc.

    SC 13D/A - Cohen & Co Inc. (0001270436) (Subject)

    12/3/24 4:17:31 PM ET
    $COHN
    Investment Bankers/Brokers/Service
    Finance